Incyte (INCY) Return on Capital Employed Growth (3y) (2014 - 2026)

Incyte (INCY) Return on Capital Employed Growth (3y) (2014 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE Growth (3y) (Qtr)
1 Oculis Holding AG 67,222.41 Bn 67,222.13 Bn - -
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.12 Bn 466.33 Bn 1.35 Bn 4,893.00
5 Vertex Pharmaceuticals 121.84 Bn 114.59 Bn 2.59 Bn -494.00
6 Regeneron Pharmaceuticals 69.89 Bn 61.14 Bn 3.31 Bn -649.00
7 Belite Bio 62.74 Bn 62.74 Bn - -
8 Argenx Se 55.83 Bn 50.64 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.34 Bn 34.34 Bn 959.66 Mn 4,853.00
10 Incyte 23.83 Bn 19.81 Bn 1.17 Bn 1,833.00

Historic Data

Download Data
DateValue
Mar 31, 2026 1,833.00
Dec 31, 2025 1,671.00
Sep 30, 2025 1,719.00
Jun 30, 2025 942.00
Mar 31, 2025 -1,019.00
Dec 31, 2024 -1,407.00
Sep 30, 2024 -2,090.00
Jun 30, 2024 -1,276.00
Mar 31, 2024 -435.00
Dec 31, 2023 2,102.00
Sep 30, 2023 2,227.00
Jun 30, 2023 1,715.00
Mar 31, 2023 2,313.00
Dec 31, 2022 -1,840.00
Sep 30, 2022 -1,317.00
Jun 30, 2022 533.00
Mar 31, 2022 311.00
Dec 31, 2021 979.00
Sep 30, 2021 2,287.00
Jun 30, 2021 1,821.00